Research Article

Lamotrigine induced seizures in juvenile myoclonic epilepsy

Volume: 30 Number: 2 July 31, 2013
  • Betül Acar
  • Ersel Dağ
  • Yakup Türkel
EN

Lamotrigine induced seizures in juvenile myoclonic epilepsy

Abstract

Juvenile myoclonic epilepsy (JME) is a common epileptic syndrome. Before the development of the new antiepileptic drugs (AEDs) after the 1990s, Valproate (VPA) was the first-line treatment in juvenile myoclonic epilepsy. However, the frequent adverse effects and the risk for teratogenicity have resulted in a search for alternative therapies especially in women. Lamotrigine (LTG), topiramate, and levetiracetam, have been used as monotherapy or adjunctive therapy for juvenile myoclonic epilepsy in small patient series. We report a case of a thirty one-years-old female suffered from severe aggravation in myoclonic and generalized tonic-clonic (GTC) seizures after decreasing the lose of VPA and initiating LTG.

Keywords

References

  1. Atakli, D., Sözüer, D., Atay, T., Baybas, S., Arpaci, B., 1998. Misdiagnosis and treatment in juvenile myoclonic epilepsy. Seizure 7, 63-66. Auvin, S., 2008. Treatment of juvenile myoclonic epilepsy. CNS Neurosci. Ther. 14, 227-233.
  2. Bodenstein-Sachar, H., Gandelman-Marton, R., Ben-Zeev, B., Chapman, J., Blatt, I., 2011. Outcome of LTG treatment in juvenile myoclonic epilepsy. Acta Neurol. Scand. 124, 22-27.
  3. Crespel, A., Genton, P., Berramdane, M., Coubes, P., Monicard, C., Baldy-Moulinier M., Gelisse, P., 2005. LTG associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology. 65, 762-764.
  4. Duncan, S., 2007. Teratogenesis of sodium VPA. Curr. Opin. Neurol. 20, 175-180.
  5. Janszky, J., Rásonyi, G., Halász, P., Olajos, S., Perenyi, J., 2000. Disabling erratic myoclonus during lamotrigine therapy with high serum level-report of two cases. Clin. Neuropharmacol. 23, 86-89.
  6. Mantoan, L., Walker, M., 2011. Treatment options in juvenile myoclonic epilepsy. Curr. Treat. Options Neurol. 13, 355-370.
  7. Mehndiratta, M.M., Aggarwal, P., 2002. Clinical expression and EEG features of patients with juvenile myoclonic epilepsy (JME) from North India. Seizure. 11, 431-436.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Authors

Betül Acar This is me

Ersel Dağ This is me

Yakup Türkel This is me

Publication Date

July 31, 2013

Submission Date

April 15, 2013

Acceptance Date

-

Published in Issue

Year 2013 Volume: 30 Number: 2

APA
Acar, B., Dağ, E., & Türkel, Y. (2013). Lamotrigine induced seizures in juvenile myoclonic epilepsy. Deneysel Ve Klinik Tıp Dergisi, 30(2), 207-208. https://doi.org/10.5835/jecm.omu.30.02.027
AMA
1.Acar B, Dağ E, Türkel Y. Lamotrigine induced seizures in juvenile myoclonic epilepsy. J. Exp. Clin. Med. 2013;30(2):207-208. doi:10.5835/jecm.omu.30.02.027
Chicago
Acar, Betül, Ersel Dağ, and Yakup Türkel. 2013. “Lamotrigine Induced Seizures in Juvenile Myoclonic Epilepsy”. Deneysel Ve Klinik Tıp Dergisi 30 (2): 207-8. https://doi.org/10.5835/jecm.omu.30.02.027.
EndNote
Acar B, Dağ E, Türkel Y (July 1, 2013) Lamotrigine induced seizures in juvenile myoclonic epilepsy. Deneysel ve Klinik Tıp Dergisi 30 2 207–208.
IEEE
[1]B. Acar, E. Dağ, and Y. Türkel, “Lamotrigine induced seizures in juvenile myoclonic epilepsy”, J. Exp. Clin. Med., vol. 30, no. 2, pp. 207–208, July 2013, doi: 10.5835/jecm.omu.30.02.027.
ISNAD
Acar, Betül - Dağ, Ersel - Türkel, Yakup. “Lamotrigine Induced Seizures in Juvenile Myoclonic Epilepsy”. Deneysel ve Klinik Tıp Dergisi 30/2 (July 1, 2013): 207-208. https://doi.org/10.5835/jecm.omu.30.02.027.
JAMA
1.Acar B, Dağ E, Türkel Y. Lamotrigine induced seizures in juvenile myoclonic epilepsy. J. Exp. Clin. Med. 2013;30:207–208.
MLA
Acar, Betül, et al. “Lamotrigine Induced Seizures in Juvenile Myoclonic Epilepsy”. Deneysel Ve Klinik Tıp Dergisi, vol. 30, no. 2, July 2013, pp. 207-8, doi:10.5835/jecm.omu.30.02.027.
Vancouver
1.Betül Acar, Ersel Dağ, Yakup Türkel. Lamotrigine induced seizures in juvenile myoclonic epilepsy. J. Exp. Clin. Med. 2013 Jul. 1;30(2):207-8. doi:10.5835/jecm.omu.30.02.027